Skip to main content
Fig. 1 | European Journal of Medical Research

Fig. 1

From: EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms

Fig. 1

EXTL3 gene expression and survival prognosis in PCa: A EXTL3 mRNA expressions in pan-cancer from TCGA; B EXTL3 mRNA expressions in PCa from TCGA; C survival analysis of EXTL3 in PCa from TCGA; immunohistochemistry of EXTL3 protein expression in D normal prostate tissues and E PCa tissues from HPA database; *P < 0.05; **P < 0.01;***P < 0.001

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us